![Jean-Paul Renaud](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Jean-Paul Renaud is associated with two companies, NovAliX SAS and Urania Therapeutics SAS.
He was the Chief Scientific Officer at NovAliX SAS, which was founded in 2002.
At Urania Therapeutics SAS, he is the President, Director, and Chief Scientific Officer, and the company was founded in 2015.
Jean-Paul Renaud active positions
Companies | Position | Start |
---|---|---|
Urania Therapeutics SAS
![]() Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Founder | 30/09/2015 |
Former positions of Jean-Paul Renaud
Companies | Position | End |
---|---|---|
NovAliX SAS
![]() NovAliX SAS BiotechnologyHealth Technology NovAliX SAS operates as a drug discovery-focused contract research organization. It offers drug discovery services in the fields of chemistry, collaborative models, biophysics and biology. The company was founded by Stephan Jenn and Jean-Paul Renaud in 2002 and is headquartered in Illkirch, France. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
NovAliX SAS
![]() NovAliX SAS BiotechnologyHealth Technology NovAliX SAS operates as a drug discovery-focused contract research organization. It offers drug discovery services in the fields of chemistry, collaborative models, biophysics and biology. The company was founded by Stephan Jenn and Jean-Paul Renaud in 2002 and is headquartered in Illkirch, France. | Health Technology |
Urania Therapeutics SAS
![]() Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Health Technology |
- Stock Market
- Insiders
- Jean-Paul Renaud